**References: Patrick Holford**

**Incidence and prevalence of AD/dementia**

WHO – 27,000 dementia diagnosis a day

<https://www.who.int/news-room/fact-sheets/detail/dementia>

**Dementia prevention, intervention, and care: 2020 report of the Lancet Commission**

Livingston G; et al. 2020 Aug 8;396(10248):413-446.

<https://doi.org/10.1016/S0140-6736(20)30367-6>

**Dementia prevention, intervention, and care.**

Livingston G; et al. Lancet 390, 2673-2734

<https://doi.org/10.1016/S0140-6736(17)31363-6>

**Definition of AD, dementia, MCI**

**Imaging the progression of Alzheimer pathology through the brain.**

Smith AD; Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4135-7.

[doi.org/10.1073/pnas.082107399](10.1073/pnas.082107399)

**Mild cognitive impairment and preclinical Alzheimer's disease**

Morris JC; Geriatrics. 2005 Jun;Suppl:9-14. PMID: 16025770

**Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.**

Winblad B; et al. J Intern Med 2004 Sep;256(3):240-6

<https://doi.org/10.1111/j.1365-2796.2004.01380.x>

**Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease.**

De Jager CA; Psychol Med. 2003 Aug;33(6):1039-50.

<https://doi.org/10.1017/S0033291703008031>

**Attention and executive deficits in Alzheimer's disease. A critical review.**

Perry RJ, Hodges JR. Brain. 1999 Mar;122 ( Pt 3):383-404.

<https://doi.org/10.1093/brain/122.3.383>

**Predicting the time of conversion to MCI in the elderly: role of verbal expression and learning.**

Oulhaj A; et al.Neurology. 2009 Nov 3;73(18):1436-42.

<https://doi.org/10.1212/WNL.0b013e3181c0665f>

**Obesity and metabolic syndrome and functional and structural brain impairments in adolescence.**

Yau PL; et al. Pediatrics. 2012 Oct;130(4):e856-64.

<https://doi.org/10.1542/peds.2012-0324>

**Midlife lipid and glucose levels are associated with Alzheimer's disease.**

Zhang X; et al. Alzheimers Dement. 2023 Jan;19(1):181-193. D

<https://doi.org/10.1002/alz.12641>

**Do genes cause AD?**

**Genetics of Alzheimer disease**

Bekris LM;et al. J Geriatric Psychiatry Neurol. 2010 Dec;23(4):213-27.

[doi: 10.1177/0891988710383571](doi:%2010.1177/0891988710383571)

**Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers**

Norwitz N.G;et al Nutrients 2021, 13, 1362.

[https://doi.org/10.3390/ nu13041362](https://doi.org/10.3390/%20nu13041362)

**A unifying hypothesis of Alzheimer’s disease**

Heininger K; et al. Hum. Psychopharmacol. Clin. Exp., 15: 1-70.

[https://doi.org/10.1002/(SICI)1099-1077(200001)15:1<1::AID-HUP153>3.0.CO;2-1](https://doi.org/10.1002/(SICI)1099-1077(200001)15:1%3c1::AID-HUP153%3e3.0.CO;2-1);

**Alzheimer’s Disease: Analyzing the Missing Heritability.**

Ridge PG; et al. (2013) PLoS ONE 8(11): e79771.

<https://doi.org/10.1371/journal.pone.0079771>

**New insights into the genetic etiology of Alzheimer’s disease and related dementias.**

Bellenguez C;et al. Nat Genet 54, 412–436 (2022).

<https://doi.org/10.1038/s41588-022-01024-z>

**Polygenic risk score analysis of pathologically confirmed Alzheimer disease.**

Escott-Price; et al. Ann Neurol. 2017 Aug;82(2):311-314.

<https://doi.org/10.1002/ana.24999>

**Apoe4 exaggeration and diet trials**

**Association between healthy lifestyle and memory decline in older adults: 10 year, population based, prospective cohort study**

Jia J; et al., BMJ 2023;380:e072691

[http://dx.doi.org/10.1136/ bmj-2022-072691](http://dx.doi.org/10.1136/%20bmj-2022-072691)

**A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.**

Ngandu T; et al. Lancet. 2015 Jun 6;385(9984):2255-63.

<10.1016/S0140-6736(15)60461-5>

**Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial.**

Solomon A; et al. JAMA Neurol. 2018 Apr 1;75(4):462-470.

<10.1001/jamaneurol.2017.4365>

**Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment.**

Douaud G; et al. Proc Natl Acad Sci

<10.1073/pnas.1301816110>

**Brain atrophy in cognitively impaired elderly: the importance of long-chain omega-3 fatty acids and B vitamin status in a randomized controlled trial.**

Jernerén F; et al. Am J Clin Nutr 2015; 102: 215-21.

<https://doi.org/10.3945/ajcn.114.103283>

**Omega-3 fatty acid status enhances the prevention of cognitive decline by B vitamins in Mild Cognitive Impairment**

Oulhaj A, Jernerén F, Refsum H, Smith AD, de Jager CA. J Alzheimer's Dis 2016; 50: 547-57.

<10.3233/JAD-150777>

**DHA status influences effects of B-vitamin supplementation on cognitive ageing: a post-hoc analysis of the B-proof trial.**

van Soest, A.P.M., van de Rest, O., Witkamp, R.F. *et al.* *Eur J Nutr* (2022). <https://doi.org/10.1007/s00394-022-02924-w>

**Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials.**

Yu JT;et al. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209.

<10.1136/jnnp-2019-321913>

**Studies Assessing Population Attributable Risk**

**Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis.**

Beydoun MA; et al. BMC Public Health. 2014 Jun 24;14:643.

<10.1186/1471-2458-14-643>

**Evidence-based prevention of Alzheimer’s disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials**

Yu JT; et al. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209.

<10.1136/jnnp-2019-321913>

**Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.**

Livingston G; et al. Lancet. 2020 Aug 8;396(10248):413-446.

<10.1016/S0140-6736(20)30367-6>

**Healthy Lifestyles Reduce the Incidence of Chronic Diseases and Dementia: Evidence from the Caerphilly Cohort Study.**

Elwood P; et al. (2013). PLoS ONE 8(12): e81877.

<https://doi.org/10.1371/journal.pone.0081877>

**Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data.**

Norton S; et al. Lancet Neurol 2014;13(8):788-94

<https://doi.org/10.1016/S1474-4422(14)70136-X>

**An Estimate of Attributable Cases of AD and VaD due to Modifiable Risk Factors.**

Ashby-Mitchell K et al. Alzheimer’s Research & Therapy (2017) 9:11

<10.1186/s13195-017-0238-x>

Cerebral small vessel disease mediates the association between homocysteine and cognitive function.

Teng Z; et al. (2022). *Front. Aging Neurosci.* 14:868777.

<https://doi.org/10.3389/fnagi.2022.868777>

**A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease.**

Selley ML. Neurobiol Aging. 2007 Dec;28(12):1834-9.

<10.1016/j.neurobiolaging.2006.08.003>

**DHA-PC and PSD-95 decrease after loss of synaptophysin and before neuronal loss in patients with Alzheimer's disease.**

Yuki D; et al. Sci Rep. 2014 Nov 20;4:7130.

<10.1038/srep07130>

**Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial.**

[Jernerén F; et al.Am J Clin Nutr. 2015 Jul;102(1):215-21](http://www.ncbi.nlm.nih.gov/pubmed/25877495)

<10.3945/ajcn.114.103283>